GB491 plus letrozole for HR+ HER2- advanced breast cancer
Part of Cancer, Skin clinical trials.
This Phase 3 study tests whether GB491 used together with letrozole works better for hormone receptor–positive and HER2-negative advanced breast cancer. You may be eligible if you have not had certain prior cancer treatments and your health tests are within safe limits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old.
- Your breast cancer is confirmed as hormone receptor–positive (HR+) and HER2-negative (HER2-).
- You have not had any prior “systematic” (full-body) cancer treatment for advanced or metastatic breast cancer.
- You have good day-to-day function (ECOG 0–1) and adequate blood/organ health based on screening labs.
- You have not used another CDK4/6 inhibitor (a type of targeted breast-cancer medicine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral drug, BTX-9341, for people with advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have already had certain treatments, including a CDK4/6 inhibitor. The goal is to see if it is safe and effective.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This Phase 2 study tests a combination of immune-based treatments along with hormone (endocrine) therapy to slow or shrink advanced, hormone-receptor positive, HER2-negative breast cancer. You may be a candidate if your cancer has progressed after standard hormone-blocking medicines and you can start treatment with CDK4/6 medicine plus an aromatase inhibitor.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.